Research Article: Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable intermediate-risk prostate cancer—a protocol for a randomised controlled trial
Abstract:
Introduction Prostate cancer (PCa) is men’s second most predominant cancer worldwide. Because the prostate-specific antigen test is used in diagnostics, PCa is more often diagnosed in the early stages, making radical treatment of the disease possible. However, it is estimated that over a million men worldwide suffer from radical treatment-related complications. Thus, focal treatment has been proposed as a solution, which aims to destroy the predominant lesson that determines the progression of the disease. The main objective of our study is to compare the quality of life and efficacy of patients diagnosed with PCa before and after the treatment with focal high-dose-rate brachytherapy and to compare results with focal low-dose-rate brachytherapy and active surveillance. Methods and analysis 150 patients diagnosed with low-risk or favourable intermediate-risk PCa who meet the inclusion criteria will be enrolled in the study. Patients are going to be randomly assigned to the study groups: focal high-dose-rate brachytherapy (group 1), focal low-dose-rate brachytherapy (group 2) and active surveillance (group 3). The study’s primary outcomes are quality of life after the procedure and time without biochemical disease recurrence. The secondary outcomes are early and late genitourinary and gastrointestinal reactions after the focal high-dose and low-dose-rate brachytherapies and evaluation of the importance and significance of in vivo dosimetry used for high-dose-rate brachytherapy. Ethics and dissemination Bioethics committee approval was obtained before this study. The trial results will be published in peer-reviewed journals and at conferences. Trial registration number Vilnius regional bioethics committee; approval ID 2022/6-1438-911.
Introduction:
Prostate cancer (PCa) is the second most predominant cancer and fifth on the list of the leading cause of death between malignancies among men worldwide. 1 Early diagnosis of PCa and timely applied effective treatment methods made it possible to increase the 5-year survival rate of patients with PCa from 65% described in the European cancer registry (EUROCARE)-3 study to 83% described in the EUROCARE-5 study. 2 3 This improvement is associated with the use of prostate-specific antigen (PSA) testing in the…
Read more